

1 **Similar viral loads in Omicron infections regardless of** 2 **vaccination status**

3
4 Yosuke Hirotsu^{1*}, Makoto Maejima², Masahiro Shibusawa², Yume Natori², Yuki Nagakubo^{2,3},
5 Kazuhiro Hosaka², Hitomi Sueki², Hitoshi Mochizuki^{1,4,5}, Toshiharu Tsutsui⁶, Yumiko
6 Kakizaki⁶, Yoshihiro Miyashita⁶, and Masao Omata^{5,7}

7
8 ¹Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi,
9 Japan

10 ²Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi,
11 Kofu, Yamanashi, Japan

12 ³Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi,
13 Kofu, Yamanashi, Japan

14 ⁴Central Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi,
15 Japan

16 ⁵Department of Gastroenterology, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu,
17 Yamanashi, Japan

18 ⁶Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi,
19 Kofu, Yamanashi, Japan

20 ⁷The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan

21
22 *Corresponding author: Yosuke Hirotsu, Genome Analysis Center, Yamanashi Central
23 Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan

24 Email: hirotsu-bdyu@ych.pref.yamanashi.jp

25 Tel: +81-55-253-7111, Fax: +81-55-253-8011

26 ORCID iD: 0000-0002-8002-834X

27 Keywords: SARS-CoV-2, variant of concern, Omicron, BA.1.1, BA.2

28 Running title: Viral loads in Omicron breakthrough infection

29

30 **Abstract**

31 **Background**

32 Although SARS-CoV-2 booster vaccinations are underway, breakthrough infections
33 with Omicron variants are occurring. This study analyzed associations between Omicron
34 sublineage (BA.1.1 and BA.2) viral load and vaccination history.

35 **Methods**

36 Viral loads in nasopharyngeal swabs were evaluated by quantitative real-time PCR,
37 and the virus strain was evaluated by whole-genome analysis or TaqMan assay.

38 **Results**

39 A total of 611 patients positive for an Omicron SARS-CoV-2 variant were included;
40 199 were unvaccinated, 370 had received two vaccine doses, and 42 had received three
41 doses. Similar viral loads and Ct values of BA.1.1 and BA.2 were detected regardless of
42 vaccination history. No correlations between age and BA.1.1 and BA.2 viral load were
43 observed.

44 **Conclusion**

45 Omicron-infected patients who had received a third vaccine dose had viral loads
46 similar to patients with two doses or who were unvaccinated.

47

48 **Introduction**

49 The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
50 has caused an estimated 497 million cases of coronavirus disease 2019 (COVID-19) and
51 6.18 million deaths worldwide. SARS-CoV-2 has acquired mutations throughout its evolution,
52 driving the emergence of new viral strains. To date, five variants of concern have been
53 designated by the World Health Organization: Alpha, Beta, Gamma, Delta, and Omicron.
54 Omicron emerged in South Africa in 2021 and has spread worldwide. Unlike other variants
55 of concern, the Omicron variant has approximately 30 mutations in its spike protein. Some
56 of its mutations (e.g., 69-70del, T95I, G142D/143-145del, K417N, T478K, N501Y, N655Y,
57 N679K, and P681H) are also present in the Alpha, Beta, Gamma, and/or Delta variants.
58 These mutations lead to increased transmissibility, increased viral binding affinity, and
59 increased immune escape [1].

60 Several Omicron sublineages have been reported; BA.1 and BA.1.1 were initially
61 most prevalent, but BA.2 is now predominating. Antibody activity against BA.1/BA.1.1 and
62 BA.2 differs because the viruses have different mutations in the spike protein [2, 3]. A
63 booster dose restores effectiveness in preventing infection and reduces disease severity
64 [4-6]. Nevertheless, breakthrough infections with Omicron variants have been reported after
65 a third dose [7, 8]. Thus, it is important to understand the virus levels that are typically
66 present after breakthrough infection to better evaluate infection control, quarantine, and
67 public health measures. However, the viral loads in cases of Omicron breakthrough infection
68 after booster vaccination are not fully clear.

69 Patients infected with Omicron BA.1.1 or BA.2 were included in this study
70 regardless of vaccination history, and nasopharyngeal swabs were used to measure viral
71 loads.

72 **Methods**

73 ***SARS-CoV-2 diagnostic testing***

74 We performed SARS-CoV-2 diagnostic testing on samples collected from January
75 10, 2022 to April 7, 2022. The following diagnostic testing platforms were used in this study:
76 COVID-19 reverse transcription-PCR performed in accordance with the protocol developed
77 by the National Institute of Infectious Diseases in Japan [9], the FilmArray Respiratory Panel
78 2.1 test performed with the FilmArray Torch system (bioMérieux, Marcy-l'Etoile, France) [10],
79 the Xpert Xpress SARS-CoV-2 test performed on a Cepheid GeneXpert system (Cepheid,
80 Sunnyvale, CA, USA) [11], and the Lumipulse antigen test performed on a LUMIPULSE
81 G600II system (Fujirebio, Inc., Tokyo, Japan) [12, 13]. All tests were conducted on material
82 obtained from nasopharyngeal swabs immersed in viral transport media (Copan, Murrieta,
83

84 CA, USA).

85

86 **Quantitative reverse transcription-PCR (RT-qPCR)**

87 To detect SARS-CoV-2, we performed one-step RT-qPCR to amplify the
88 nucleocapsid (N) gene of SARS-CoV-2 as previously described [14]. The human
89 ribonuclease P protein subunit p30 (*RPP30*) gene was used as the internal positive control
90 (Integrated DNA Technologies, Coralville, IA, USA) [14]. The RT-qPCR assays were
91 performed on a StepOnePlus Real-Time PCR system (Thermo Fisher Scientific, Waltham,
92 MA, USA) with the following cycling conditions: reverse transcription at 50 °C for 5 min,
93 inactivation of reverse transcription at 95 °C for 20 s, followed by 45 cycles of denaturation
94 at 95 °C for 3 s and annealing/extension at 60 °C for 30 s. The threshold was set at 0.2. In
95 accordance with the national protocol (v. 2.9.1) [9], samples were determined to be positive
96 if a visible amplification plot was observed and negative if no amplification was observed.

97

98 **SARS-CoV-2 genome analysis**

99 Whole-genome sequencing was conducted in accordance with a previously
100 described method using the nasopharyngeal swab samples collected from
101 SARS-CoV-2-positive patients. In brief, SARS-CoV-2 genomic RNA was
102 reverse-transcribed into cDNA and amplified using the Ion AmpliSeq SARS-CoV-2
103 Research Panel or the Ion AmpliSeq SARS-CoV-2 Insight Research Assay (Thermo Fisher
104 Scientific) on the Ion Torrent Genexus system in accordance with the manufacturer's
105 instructions [15-17]. The sequencing reads were processed and their quality assessed using
106 Genexus software with SARS-CoV-2 plugins. The sequencing reads were then mapped and
107 aligned using the torrent mapping alignment program. After initial mapping, a variant call
108 was performed using the Torrent Variant Caller. The COVID19AnnotateSnEff plugin was
109 used to annotate the variants. Assembly was performed using Iterative Refinement
110 Meta-Assembler [18].

111 The viral clade and lineage classifications were conducted using Nextstrain [19]
112 and Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) [20]. The
113 sequence data were deposited in the Global Initiative on Sharing Avian Influenza Data
114 (GISAID) EpiCoV database [21].

115

116 **TaqMan assay**

117 We used the pre-designed TaqMan SARS-CoV-2 Mutation Panel to detect
118 SARS-CoV-2 spike $\Delta 69-70$, G339D, L452R, and Q493R (Thermo Fisher Scientific) in
119 SARS-CoV-2-positive samples [22]. The TaqMan MGB probe for the wild-type allele was

120 labeled with VIC dye, and the probe for the variant allele was labeled with FAM dye. This
121 TaqMan probe system can detect both wild-type and variant sequences of SARS-CoV-2.
122 TaqPath 1-Step RT-qPCR Master Mix CG was used as master mix. Real-time PCR was
123 conducted on a Step-One Plus Real-Time PCR system (Thermo Fisher Scientific).

124

125 **Statistical analysis**

126 All statistical tests and visualizations were performed with R (v4.1.1) or RStudio
127 (<http://www.r-project.org/>). Plotting in R also made use of the ggplot2 (v3.3.5), dplyr (v1.0.7),
128 tidyr (v1.1.3), patchwork (v1.1.1), gtsummary (v1.5.2), and flextable (v.0.7.0) packages.
129 Bartlett's test was used to test for equality of variances. Statistical analyses (Kruskal–Wallis
130 rank–sum test; Pearson's chi-square test; Fisher's exact test, pairwise t-test with Holm
131 correction, Pearson's product–moment correlation coefficient) were conducted. P-values <
132 0.05 were considered statistically significant.

133

134 **Results**

135 **Vaccination history and Omicron infection**

136 This study included 611 patients who were diagnosed as SARS-CoV-2-positive
137 between January 10, 2022 and April 7, 2022. The vaccination history of the patients was as
138 follows: 199 were unvaccinated, 370 had received two doses of vaccine, and 42 had
139 received three doses of vaccine. The median ages were 14 years (IQR: 19, 60) for the
140 unvaccinated group, 44 years (IQR: 28, 68) for the two-dose group, and 48 years (IQR: 34,
141 70) for the three-dose group (Table 1, $p < 0.001$). The vaccination status by age was
142 consistent with the priority given to older adults to receive a third dose. No significant
143 differences were found between vaccination history and sex ($p = 0.7$) or disease severity (p
144 $= 0.2$) (Table 1).

145 Whole-genome sequencing or TaqMan analysis was performed to identify Omicron
146 sublineages. Of the 611 patients, 453 had BA.1.1 and 158 had BA.2. In those who had
147 received a third dose, BA.2 (15.2%, 24/158) was more often detected than BA.1.1 (4.0%,
148 18/453). These results indicate that BA.2 is better able than BA.1.1 to cause breakthrough
149 infection in those who have received a booster dose.

150

151 **Vaccination history and viral load in patients infected with Omicron**

152 To analyze whether vaccination history altered the viral load after infection with the
153 Omicron sublineages, we quantitatively assessed viral load in nasopharyngeal swabs by
154 RT-qPCR (Figure 1). In BA.1.1-infected individuals, the mean viral loads \pm SD were $5.3 \pm$
155 1.4 (range: -0.9 – 7.8) in the unvaccinated group, 5.4 ± 1.5 (-0.3 – 7.7) in the two-dose group,

156 and 4.6 ± 1.7 (2.2–6.8) in the three-dose group, while they were 5.4 ± 1.6 (range: 1.0–7.7),
157 5.8 ± 1.5 (-0.4–8.2), and 5.5 ± 1.7 (0.5–7.9), respectively, in the BA.2-infected individuals
158 (Figure 1A). In BA.1.1-infected individuals, the mean cycle thresholds (Ct) \pm SD were $20.5 \pm$
159 5.1 (range: 12–44) in the unvaccinated group, 20.2 ± 5.1 (12–38) in the two-dose group, and
160 22.5 ± 5.7 (15–31) in the three-dose group, while they were 19.9 ± 5.6 (range: 12–35), 18.4
161 ± 5.0 (11–37), and 19.9 ± 6.0 (12–38), respectively, in the BA.2-infected individuals (Figure
162 1B). No significant differences in viral load or Ct values were found among the groups with
163 different vaccination histories ($p > 0.05$, pairwise t-test with Holm correction).

164 We next analyzed whether the viral load after vaccination was correlated with age
165 (Figures 1C and 1D). For those with BA.1.1 infection, the correlation coefficients between
166 age and viral load were $r = -0.023$ ($p = 0.80$) for the unvaccinated, $r = -0.055$ ($p = 0.35$) for
167 the two-dose group, and $r = -0.189$ ($p = 0.45$) for the three-dose group, while for those with
168 BA.2 infection they were $r = 0.129$ ($p = 0.31$), $r = -0.084$ ($p = 0.49$), and $r = 0.189$ ($p = 0.38$),
169 respectively (Figure 1C). For those with BA.1.1 infection, the correlation coefficients
170 between age and Ct value were $r = 0.017$ ($p = 0.85$) for the unvaccinated, $r = 0.058$ ($p =$
171 0.32) for the two-dose group, and $r = 0.195$ ($p = 0.44$) for the three-dose group, while for
172 those with BA.2 infection they were $r = -0.122$ ($p = 0.34$), $r = 0.095$ ($p = 0.43$), and $r = -0.159$
173 ($p = 0.46$), respectively (Figures 1D). There was no correlation between age and the viral
174 load, regardless of vaccination history ($p > 0.05$, Pearson's correlation coefficient), indicating
175 that when breakthrough infection occurs, the virus can achieve a high viral load regardless
176 of vaccination history and age.

177

178 Discussion

179 We analyzed the amount of virus present in nasopharyngeal swab samples from
180 patients who became infected even after receiving a third vaccine dose. These patients
181 showed similar amounts of virus as unvaccinated patients. This was consistent with our
182 finding that patients produced a similar amount of virus regardless of age. To our knowledge,
183 this is the first study of viral loads in patients infected with the Omicron BA.1.1 and BA.2
184 sublineages post vaccination. The findings indicate the potential for secondary transmission
185 from infected individuals even after they have received a booster vaccination. Therefore,
186 non-pharmaceutical interventions, such as mask-wearing and physical distancing, are
187 necessary to prevent the transmission of Omicron variants from both vaccinated and
188 unvaccinated individuals.

189 The rapid spread of the Omicron variant worldwide has led to its replacement of the
190 Delta variant [21]. Omicron has multiple mutations in the spike protein, raising concerns that
191 antibodies may be less effective than they were against the ancestral strain and other

192 variants of concern [23-25]. Booster vaccination can lower the risk of infection with Omicron,
193 but the protection weakens over time [4, 6]. Infections have been reported despite high
194 levels of anti-spike antibodies after the third vaccination [7]. Our data indicate the need to
195 maintain non-pharmaceutical measures (e.g., mask use, ventilation, physical distancing) to
196 suppress the spread of infection because high viral loads were found even after individuals
197 had received a booster vaccination.

198 This study had limitations. First, it did not assess the amount of culturable, viable
199 virus, so it is unknown whether the detections represented infectious virus. Second, it did
200 not take into account the time since vaccination, and there may have been variation in
201 antibody titers. Third, there may be bias because the number of vaccine doses differed with
202 age. Therefore, further analysis with a larger sample size is needed.

203 In summary, individuals infected with the Omicron variant might still be able to
204 produce infectious virus even if they have received a booster vaccination. Therefore,
205 isolating patients with a breakthrough infection could help mitigate the spread of
206 SARS-CoV-2.

207

208 **Acknowledgments**

209 We thank all medical and ancillary hospital staff for their support. We also thank Katherine
210 Thieltges from Edanz (<https://jp.edanz.com/ac>) for editing a draft of this manuscript.

211

212 **Funding:** This work was supported by a Grant-in-Aid for the Genome Research Project from
213 Yamanashi Prefecture (to M.O. and Y.H.), the Japan Society for the Promotion of Science
214 KAKENHI Early-Career Scientists JP18K16292 (to Y.H.), a Grant-in-Aid for Scientific
215 Research (B) 20H03668 (to Y.H.), a Research Grant for Young Scholars (to Y.H.), the
216 YASUDA Medical Foundation (to Y.H.), the Uehara Memorial Foundation (to Y.H.), and
217 medical research grants from the Takeda Science Foundation (to Y.H.).

218

219 **Declaration of interest**

220 None to declare.

221

222 **References**

- 223 1. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete
224 Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody
225 Recognition. *Cell Host & Microbe*. 2021;29(1):44-57.e9. doi:
226 <https://doi.org/10.1016/j.chom.2020.11.007>.
- 227 2. Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I, et al. Serum neutralization of

- 228 SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
229 Nature Medicine. 2022. doi: 10.1038/s41591-022-01792-5.
- 230 3. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. The Omicron
231 variant is highly resistant against antibody-mediated neutralization: Implications for control of the
232 COVID-19 pandemic. Cell. 2021. doi: <https://doi.org/10.1016/j.cell.2021.12.032>.
- 233 4. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19
234 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of
235 Medicine. 2022. doi: 10.1056/NEJMoa2119451.
- 236 5. Moreira ED, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and
237 Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. New England Journal of Medicine.
238 2022. doi: 10.1056/NEJMoa2200674.
- 239 6. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al.
240 Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. New England Journal of
241 Medicine. 2022. doi: 10.1056/NEJMoa2201570.
- 242 7. Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al.
243 Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. The
244 Lancet. 2022;399(10325):625-6. doi: 10.1016/S0140-6736(22)00090-3.
- 245 8. Marking U, Havervall S, Norin NG, Christ W, Gordon M, Ng H, et al. High rate of BA.1,
246 BA.1.1 and BA.2 infection in triple vaccinated. medRxiv. 2022:2022.04.02.22273333. doi:
247 10.1101/2022.04.02.22273333.
- 248 9. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of
249 Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis.
250 2020;73(4):304-7 doi: 10.7883/yoken.JJID.2020.061. PubMed PMID: 32074516.
- 251 10. Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, et al.
252 Analysis of Covid-19 and non-Covid-19 viruses, including influenza viruses, to determine the
253 influence of intensive preventive measures in Japan. J Clin Virol. 2020;129:104543. doi:
254 10.1016/j.jcv.2020.104543
- 255 11. Hirotsu Y, Maejima M, Shibusawa M, Natori Y, Nagakubo Y, Hosaka K, et al. Direct
256 comparison of Xpert Xpress, FilmArray Respiratory Panel, Lumipulse antigen test, and RT-qPCR
257 in 165 nasopharyngeal swabs. BMC Infectious Diseases. 2022;22(1):221. doi:
258 10.1186/s12879-022-07185-w.
- 259 12. Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, et al.
260 Prospective Study of 1,308 Nasopharyngeal Swabs from 1,033 Patients using the LUMIPULSE
261 SARS-CoV-2 Antigen Test: Comparison with RT-qPCR. International Journal of Infectious
262 Diseases. 2021. doi: <https://doi.org/10.1016/j.ijid.2021.02.005>.
- 263 13. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al.

- 264 Comparison of Automated SARS-CoV-2 Antigen Test for COVID-19 Infection with Quantitative
265 RT-PCR using 313 Nasopharyngeal Swabs Including from 7 Serially Followed Patients.
266 International Journal of Infectious Diseases. 2020. doi: <https://doi.org/10.1016/j.ijid.2020.08.029>.
- 267 14. Hirotsu Y, Mochizuki H, Omata M. Double-quencher probes improve detection
268 sensitivity toward Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a
269 reverse-transcription polymerase chain reaction (RT-PCR) assay J Virol Methods.
270 2020;284:113926. doi: 10.1016/j.jviromet.2020.113926
- 271 15. Hirotsu Y, Omata M. Detection of R.1 lineage severe acute respiratory syndrome
272 coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan.
273 PLOS Pathogens. 2021;17(6):e1009619. doi: 10.1371/journal.ppat.1009619.
- 274 16. Hirotsu Y, Omata M. Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring
275 K417T/E484K/N501Y mutations in Kofu, Japan. Journal of Infection. 2021;82(6):276-316. doi:
276 <https://doi.org/10.1016/j.jinf.2021.03.013>.
- 277 17. Hirotsu Y, Omata M. SARS-CoV-2 B.1.1.7 lineage rapidly spreads and replaces R.1
278 lineage in Japan: Serial and stationary observation in a community. Infection, Genetics and
279 Evolution. 2021;95:105088. doi: <https://doi.org/10.1016/j.meegid.2021.105088>.
- 280 18. Shepard SS, Meno S, Bahl J, Wilson MM, Barnes J, Neuhaus E. Viral deep sequencing
281 needs an adaptive approach: IRMA, the iterative refinement meta-assembler. BMC Genomics.
282 2016;17:708. doi: 10.1186/s12864-016-3030-6. PubMed PMID: 27595578; PubMed Central
283 PMCID: PMCPMC5011931.
- 284 19. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain:
285 real-time tracking of pathogen evolution. Bioinformatics. 2018;34(23):4121-3. doi:
286 10.1093/bioinformatics/bty407. PubMed PMID: 29790939; PubMed Central PMCID:
287 PMCPMC6247931.
- 288 20. Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, et al. A dynamic
289 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol.
290 2020;5(11):1403-7. doi: 10.1038/s41564-020-0770-5. PubMed PMID: 32669681.
- 291 21. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision
292 to reality. Euro Surveill. 2017;22(13). doi: 10.2807/1560-7917.ES.2017.22.13.30494. PubMed
293 PMID: 28382917; PubMed Central PMCID: PMCPMC5388101.
- 294 22. Hirotsu Y, Maejima M, Shibusawa M, Natori Y, Nagakubo Y, Hosaka K, et al.
295 Classification of Omicron BA.1, BA.1.1 and BA.2 sublineages by TaqMan assay consistent with
296 whole genome analysis data. medRxiv. 2022:2022.04.03.22273268. doi:
297 10.1101/2022.04.03.22273268.
- 298 23. Carreño JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, et al. Activity
299 of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature.

300 2022;602(7898):682-8. doi: 10.1038/s41586-022-04399-5.

301 24. Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et al. mRNA
302 booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron
303 variant. *Nature Medicine*. 2022;28(3):477-80. doi: 10.1038/s41591-021-01676-0.

304 25. Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al. Neutralization of
305 SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera. *Science*.
306 2022;375(6581):678-80. doi: doi:10.1126/science.abn7591.

307


308 **Table 1. Patient characteristics**

Characteristic	Overall, n = 611	Unvaccinated, n = 199	2nd vaccination, n = 370	3rd vaccination, n = 42	p-value ¹
Age, median (IQR)	37 (19, 60)	14 (5, 40)	44 (28, 68)	48 (34, 70)	<0.001
Sex, n (%)					0.7
Female	290 (47%)	96 (48%)	172 (46%)	22 (52%)	
Male	321 (53%)	103 (52%)	198 (54%)	20 (48%)	
Symptom, n (%)					0.2
Mild	155 (76%)	27 (68%)	120 (80%)	8 (57%)	
Moderate I	25 (12%)	7 (18%)	15 (10%)	3 (21%)	
Moderate II	22 (11%)	5 (12%)	14 (9.3%)	3 (21%)	
Severe	2 (1.0%)	1 (2.5%)	1 (0.7%)	0 (0%)	
Unknown ²	407	159	220	28	
Lineage, n (%)					<0.001
BA.1.1	453 (74%)	136 (68%)	299 (81%)	18 (43%)	
BA.2	158 (26%)	63 (32%)	71 (19%)	24 (57%)	

¹ Kruskal–Wallis rank–sum test; Pearson's chi-square test; Fisher's exact test

² Symptoms were not assessed because the individual was an outpatient.

309



310

311

312 **Figure 1. Omicron viral load according to vaccination status**

313 **(A, B)** Box plots show viral load (A) or Ct value (B) in BA.1.11- and BA.2-infected individuals
 314 according to vaccination status: unvaccinated, 2nd dose, or 3rd dose. The viral loads and Ct
 315 values were determined by RT-qPCR. Groups were compared by pairwise t-tests. All
 316 p-values were >0.05 .

317 **(C, D)** Correlation plots show the association between age and viral load (C) or Ct value (D)
 318 in individuals infected with BA.1.11 or BA.2. Pearson's correlation coefficients (r) were all
 319 less than 0.2, indicating no correlation. The gray regression line background indicates the
 320 95% confidence interval.